Table 2 Targets of CAR-NK cell-based therapy for hematological malignancies

CD19

B-ALL

PB

scFv-4-1BB-CD3ζ

Retrovirus

[77]

2005

CD19

B-cell leukemia

PB

scFv-4-1BB-CD3ζ

mRNA electroporation

[78]

2012

CD19

B-ALL

PB

scFv-CD28-CD3ζ

Lentivirus

[79]

2016

CD19

B-cell precursor Leukemia

PB

scFv-CD28-4-1BB-CD3ζ

Retrovirus

[80]

2016

CD19

B-cell lymphoma

NK-92

scFv-CD28-4-1BB-CD3ζ

Lentivirus

[81]

2017

CD19

B-cell malignancies

UCB

scFv-4-1BB-CD3ζ + iCasp9 + IL15

Retrovirus

[82]

2018

CD19

B-cell leukemia

NK-92

scFv-4-1BB-CD3ζ

Lentivirus

[83]

2020

CD19

B-cell lymphoma and precursor leukemia

PB

scFv-4-1BB-CD3ζ + CXCR4

Lentivirus

[84]

2020

CD19

B-ALL

PB

scFv-CD28-CD3ζ

Retrovirus

[53]

2020

CD19

B-cell lymphoma

UCB

iC9 + scFv-CD28-CD3ζ + IL-15

Retrovirus

[85]

2021

CD19/BCMA

B-cell malignancies

NK-92

scFv-4-1BB-CD3ζ

mRNA electroporation

[86]

2022

CD20

Burkitt lymphoma

PB

scFv-4-1BB-CD3ζ

mRNA electroporation

[87]

2015

CD20

Burkitt lymphoma

PB

scFv-4-1BB-CD3ζ

mRNA electroporation

[88]

2017

CD138

multiple myeloma

NK-92

ScFv-CD3ζ

Lentivirus

[89]

2014

CS-1

multiple myeloma

NK-92

scFv-CD28-CD3ζ

Lentivirus

[90]

2014

BCMA

multiple myeloma

NK-92

scFv-4-1BB-CD3ζ

Lentivirus

[91]

2019

BCMA

multiple myeloma

PB

ScFv-CD3ζ/DAP12

mRNA electroporation

[92]

2022

CD38

AML

PB

scFv-CD28-CD3ζ

mRNA electroporation

[93]

2022

CD38

AML

PB

scFv-CD28-CD3ζ

mRNA electroporation

[68]

2020

CD33

AML

PB

scFv-4-1BB-CD3ζ

Lentivirus

[94]

2022

CD5

T-cell malignant cells

NK-92

scFv-CD28-4-1BB-CD3ζ

Lentivirus

[95]

2017

CD5

T-cell malignant cells

NK-92

scFv-2B4-CD3ζ

Lentivirus

[96]

2019

CD7

T-cell Leukemia

NK-92

scFv-CD28-4-1BB-CD3ζ

mRNA electroporation

[97]

2019

CD123

AML

PB

scFv-CD28-4-1BB-CD3ζ

Retrovirus

[98]

2017

CD123

AML

NK-92

scFv-CD28-4-1BB-CD3ζ

Retrovirus

[99]

2021

NKG2DL

AML

PB

NKG2D-CD28-4-1BB-CD3ζ

mRNA electroporation

[100]

2021